A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Open accessThe DOI matches its Crossref record; 327 of the 327 references it cites were found in a registry or an index; 135 of the 655 sources its claims cite were checked for support.
Abstract
Type 2 diabetes (T2D), which has currently become a global pandemic, is a metabolic disease largely characterised by impaired insulin secretion and action. Significant progress has been made in understanding T2D aetiology and pathogenesis, which is discussed in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone responsible for augmenting insulin secretion from pancreatic beta-cells during the postprandial period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much longer half-life have been developed, which are currently an effective treatment option for T2D by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, these therapies have been shown to induce weight loss in patients, suggesting they could be an alternative to bariatric surgery, a procedure associated with numerous complications. Current GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have been developed for these sites to test their therapeutic potential. Recent studies have also demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R mechanisms of activation via different agonists, will likely provide better insight into the therapeutic potential of GLP-1-based therapies to treat T2D.
Overview
CoChat Summary
TL;DR
This narrative review summarizes type 2 diabetes epidemiology, multifactorial aetiology/pathogenesis, extrapancreatic complications, and treatments, with emphasis on GLP-1 receptor-based therapies. It argues that GLP-1R agonists, including emerging allosteric and multi-receptor agonists, may improve glycaemia, weight, and systemic complications, while many mechanistic uncertainties remain.
Key findings
- T2D is described as a global pandemic: ~382 million patients globally in 2013, projected >590 million by 2035 and >700 million by 2045; T2D accounts for ~90% of diabetes cases. Obesity is a major risk factor, reported to increase T2D risk by 90-fold, and genetic susceptibility is supported by ~70% monozygotic twin concordance, 40% lifetime risk with one affected parent, and almost 70% with both parents affected.
- Pathogenesis involves beta-cell dysfunction/apoptosis, peripheral insulin resistance, alpha-cell dysregulation, islet amyloid/IAPP deposition, and a diminished incretin effect, where GLP-1 and GIP account for <20% of insulin release after glucose ingestion in T2D. Extrapancreatic pathology includes cardiovascular disease, diabetic nephropathy, neuropathy, and NAFLD, reported in ~70% of T2D patients.
- GLP-1-based therapies are central: native GLP-1 has a half-life of 1–2 minutes, whereas exenatide has 3.4–4 hours and liraglutide 11–13 hours; GLP-1R agonists augment glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and induce weight loss. In a 160-week liraglutide trial, T2D diagnosis occurred in 2% vs 6% of placebo-treated participants, and time to T2D onset was 2.7x longer with liraglutide.
- Emerging approaches include GLP-1R allosteric agonists (compounds 2 and B) and GLP-1/GIP/glucagon tri-agonists tested in rodents, which improved glycaemia, body weight, and islet architecture. Bariatric surgery can induce T2D remission—one study reported 53% complete remission at three years and another 10% partial remission—but carries complications such as vomiting/dumping syndrome, iron and B12 deficiency, and secondary hyperparathyroidism.
Methods
- Narrative review of published literature on T2D epidemiology, aetiology, pathogenesis, treatments, and future perspectives; no primary data collection or systematic search strategy is described.
- Synthesizes preclinical and clinical evidence, including rodent models, human islets, autopsy studies, and clinical trials; the main analysis is qualitative narrative synthesis.
Limitations
- The paper does not present a formal limitations section; limitations stated in the text include unresolved mechanisms, conflicting findings (e.g., glucolipotoxicity, UCP2, GIP action), uncertainty from undiagnosed diabetes in global prevalence estimates, and the caveat that animal-study observations may have limited clinical implications for humans.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal quality appraisal, and it relies on heterogeneous cited studies without meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
87 Valid · 11 Not valid · 355 Not checked · 7 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study demonstrated the importance of genetics in T2D susceptibility independently of the diet as there was a higher prevalence of the disease in the twin population compared to the singleton population77”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Aetiology
What the sources say
- Disputedcites [77] Poulsen, 2009, Diabetes sourceExperimental — accuracy not yet measured
The Discussion confirms that elderly twins had a higher prevalence of type 2 diabetes than singletons. But the Abstract’s Conclusions interpret the finding as evidence for a significant impact of the fetal environment “as opposed to genetics,” contrary to the claim that the comparison demonstrates the importance of genetics. These passages also do not establish independence from diet. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“It has been shown that a high proton motive force (PMF) results in the production of ROS, and as UCP2 activity can lower the PMF by increasing proton leak, it can then lower intracellular ROS, as well as increased production of ROS, is thought to be at least partly dependent on an increased mitochondrial PMF in islet beta-cells.180,183–185”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
What the sources say
- Supportedcites [180] Affourtit, 2011, Free Radic Biol Med source
The Discussion (‘UCP2 function and regulation’) says UCP2 contributes to mitochondrial proton leak. The Discussion (‘GSIS regulation by UCP2’) also describes UCP2 activity as partially dissipating mitochondrial membrane potential, supporting the claimed mechanism. (LLM, conf=0.92)
- Not checked yetcites [183] Pi, 2010, Diabetes Obes Metab source
- Disputedcites [184] Robson-Doucette, 2011, Diabetes sourceExperimental — accuracy not yet measured
The paper’s Results say UCP2 does not contribute to classical proton leak in β-cells, and its Discussion says the increased ROS observed after UCP2 deletion is not caused by reduced proton leak. Although the introduction acknowledges reports of UCP2-facilitated proton leak elsewhere, the paper’s findings contradict that mechanism in the islet β-cell context of the citing sentence. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“TNFα secretion from T2D subjects was higher than healthy controls,207,208 and one in vitro study has shown that this myokine impairs beta-cell function.208”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Extrapancreatic Tissues Involvement in T2D: Aetiology/Pathogenesis and Post-Diagnosis Complications
What the sources say
- Supportedcites [207] Ciaraldi, 2016, PLoS One source
The Results/Discussion of our copy state that TNFa secretion is elevated in T2D myotubes relative to non-diabetic cells: Discussion (p. n/a) says 'Our current observation that TNFa secretion, while low, is elevated in T2D myotubes is confirmatory of our earlier results', and the Discussion also summarizes 'our results that secretion of TNFa, IL6 and MCP-1 are all elevated in T2D myotubes'. The Introduction frames the same comparison against cells from non-diabetic (ND) individuals. Note the parallel circulating TNFa difference in Table 2 was not retained after BMI adjustment, but the claim concerns secretion, which the paper supports. (LLM, conf=0.90)
- Disputedcites [208] Bouzakri, 2011, Diabetes sourceExperimental — accuracy not yet measured
Our copy contains no measurement of TNF-α secretion comparing type 2 diabetic subjects with healthy controls; the study is entirely in vitro, using human myotubes rendered insulin resistant by added TNF-α (RESULTS, 'Myokine expression and secretion from human skeletal muscle cells (myotubes) treated with or without TNF-α'). On the contrary point, the DISCUSSION states 'At present, there is little evidence for elevated TNF-α in the skeletal muscle of individuals with type 2 diabetes,' and the background passage (labeled Abstract > CONCLUSIONS in our copy) says the source of increased circulating TNF-α in type 2 diabetes 'remains unclear, but it does not appear to be the muscle itself (18),' with elevated levels in obesity/T2D credited to refs 18-19 rather than shown here. So the muscle-derived ('myokine') elevation the citing sentence attributes to this source is contradicted by our copy; only the separate in vitro β-cell/GSIS impairment finding (TNF-α in TM blunting GSIS, blocked by Ethanercept) is supported. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are a range of effective treatments that reduce hyperglycaemia in T2D patients, which mediate their effects by improving insulin secretion or decreasing peripheral tissue insulin resistance.8”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [8] Raz, 2013, Diabetes Care source
The paper’s sections on individual drug classes describe several effective glucose-lowering treatments with these mechanisms. The sulfonylureas and meglitinides section says they increase insulin secretion, while the PPAR-γ: pioglitazone section says that class lowers blood glucose by reducing insulin resistance and improving insulin sensitivity in muscle. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [11] Horton, 2010, Diabetes Care source
The Conclusions report that weight loss was associated with better glycemic control in patients with type 2 diabetes. The Results (Regression analysis) specify that this benefit appeared with any weight loss in exenatide-treated patients, but only with weight loss of at least 8% in the sitagliptin and insulin groups. (LLM, conf=0.92)
- Supportedcites [12] Wilding, 2014, Int J Clin Pract source
The ‘Effects on glycaemic control’ section says that weight loss improves glycaemic control in people with T2DM and that those who lose weight are more likely to reach target HbA1c values. The ‘Message for the clinic’ and Introduction also link excess weight to cardiometabolic complications and cardiovascular risk. Page numbers are not available in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
212 more claims · 48 with their cited sources checked
Create a free account to see all 460 claims and to verify the 520 references still open.
- It may state two separate claims as one. 213
- Probably not a substantial claim. 60
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence supports the concept that deposition of ectopic fat within pancreatic islets, possibly inside β cells themselves, contributes to progressive impairment of β-cell function (which is reversible with weight loss)115 in individuals who are genetically susceptible.116–118”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“peripheral insulin resistance is a requisite precursor for the development of this disease.”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“T2D has been shown to manifest in non-overweight individuals in the absence of insulin resistance, although this is thought to be rare.140”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“exenatide has a half-life of 3.4–4 hours”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“| Exenatide (Byetta) | Twice daily | 2.4 hours | Yes |”
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 6×
“estimated that there will be over 700 million T2D patients worldwide.(1,62) However, as highlighted in”
InfluentialBiochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Research works printed but not linked: 25
- Thompson, 2013, Clin Exp Pharmacol, 1, 3
- 2010, Clinical Problems Caused by Obesity
- 2012, The Disease Burden Associated with Overweight and Obesity
- Templeman, 2017, J Endocrinol, 2017, 58
- Hu, 2011, Role Diet Lifestyle Genes, 34, 1249
- 2011, Biochemistry
- Karalliedde, 2016, Nephrol Dialysis Transplant, 31, 206
- Ali, 2010, Indian J Med Res, 132, 584
- Mazzola, 2012, Am J Manag Care, 18, 17
- Saeedi, 2019, Diabetes Res Clin Pract, 2, 157
- 1985, Diabetes in America
- Hyttinen, 2003, Nationwide Follow Up Study, 52, 1052
- Torres, 2008, Gastroenterol Hepatol (N Y), 4, 568
- Wilcox, 2005, Clin Biochemist Rev, 26, 19
- Cnop, 2005, Many Differences Few Similarities, 54, S97
- Gerich, 2000, J Clin Endocrinol Metab, 85, 2113
- Ivan Quesada, 2008, J Endocrinol, 2, 68
- Shah, 2000, J Clin Endocrinol Metab, 85, 4053
- Clark, 1988, Diabetes Res, 9, 151
- Perry, 2016, Exerc Immunol Rev, 22, 94
- Keshel, 2015, J Obes Weight Loss Ther, 5, S5
- 2018, Encyclopedia of Signaling Molecules
- Halverson, 1986, Am Surg, 52, 594
- Avinoah, 1992, Surgery, 111, 137
- 2017, Encyclopedia of Signaling Molecules
Cited by
Items 301–400 of 442
Vuyisich, M., Antoine, G., Mehrtash, M., Keiser, H., Connell, J., Ogundijo, O., Shen, N., Julian, C., Garimella, M., Banavar, G. S., et al. (2024) · Preprints.org · doi:10.20944/preprints202408.1740.v1 · Cited by 1
Tawfik, G. A. E. F., Sultan, H. E., Younis, G. A. E. L., & Emairy, W. S. E. (2022) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-022-00149-7
AbdulRahman, M. B., & El-Bashir, J. M. (2022) · Annals of Basic and Medical Sciences · doi:10.51658/abms.202231.2
Negash, Z., & Mekonen, T. (2023) · Metabolism Open · doi:10.1016/j.metop.2022.100228
“The prevalence of T2DM has grown substantially in nations of all economic levels during the past three decades [2].”
BackgroundEffects of Sheng-Mai Injection on Diabetes Mellitus: A Systematic Review and Meta-analysis
Yang, M., Hu, Z., & Yue, R. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230127121738 · Cited by 1
Nasir, A., Rao, M., Mahmud, Q., Anwar, W., Kanwal, Z., & Asghar, A. (2023) · JAIMC Journal of Allama Iqbal Medical College · doi:10.59058/jaimc.v20i3.66
SAIOC, A., Nechita, V.-I., & Puia, I. C. (2023) · Notulae Scientia Biologicae · doi:10.55779/nsb15111394
Li, J., & Aiyasamy, K. (2023) · Pharmacognosy Magazine · doi:10.1177/09731296231158479
Ragab, H. M., Maksoud, N. A. E., Amin, M. A., & Elaziz, W. A. (2023) · Research Square · doi:10.21203/rs.3.rs-2798448/v1
Kamari, N., Fateh, H. L., Darbandi, M., Najafi, F., Bonyani, M., Shakiba, E., & Pasdar, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2988845/v1
Straat, M. E., Bizino, M. B., van Eyk, H. J., Lamb, H. J., Smit, J. W. A., Jazet, I. M., de Jager, S. C. A., Boon, M. R., Martínez‐Téllez, B., & Hoekx, C. A. (2023) · Research Square · doi:10.21203/rs.3.rs-3030074/v1
Batista, L. S., de Alencar-Araripe, M. G., da Silva, R. P., Júnior, E. M. L., Aragão, G. F., & de Moraes, M. O. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.tis270.2123-2
EFEITOS DA TERAPIA PROBIÓTICA COM KEFIR DE LEITE NA OSTEOPOROSE: UMA REVISÃO DE LITERATURA
Maia, T. A. C., Vieira, L. V., Bessa, S. T., da Rocha, I. S., Leitão, M. G. S., & Gondim, D. V. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.tis270.2123-10
de Oliveira, N. A. C., & Aragão, G. F. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.tis270.2123-1
Tópicos interdisciplinares da saúde humana: perspectivas translacionais
Aragão, G. F. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.tis270.2123-0
Oprea, G., Ghidersa, M., Balmuș, I.-M., Luca, I. S., Ciobica, A. S., Guenné, S., & Cîmpeanu, M. (2023) · Annals of the Academy of Romanian Scientists Series on Biological Sciences · doi:10.56082/annalsarscibio.2023.1.82
Ying, X., Ni, G., Zhang, X., Gao, Z., Fu, S., Li, H., & Gao, Z. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4488896
Management and interplay of Type 2 Diabetes Mellitus with obesity
Hassan, A., Mohamed, N., Abdelhamid, A., Ahmed, H., & Abdelhaliem, N. (2023) · Sohag Medical Journal · doi:10.21608/smj.2023.223456.1397
Timur, W. W., Rizkiani, A. A., & Widyaningrum, N. (2022) · Cendekia Journal of Pharmacy · doi:10.31596/cjp.v6i2.215
Azarova, I. E., Klyosova, E. Y., Azarova, V., & Polonikov, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3234443/v1
Abusalem, A. A., & Albalawi, A. R. (2023) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2023.95256162
Yadav, S. S., Roham, P. H., Roy, S., & Sharma, S. (2023) · Human Gene · doi:10.1016/j.humgen.2023.201207
Irmawati, I. (2023) · Gaceta Médica de Caracas · doi:10.47307/gmc.2023.131.s4.17
Khoshnazar, S. M., Najafipour, H., SoltaniNejad, L., Pezeshki, S., & Yousefzadeh, G. (2023) · Italian Journal of Medicine · doi:10.4081/itjm.2023.1642
Insulinización en adultos mayores con diabetes mellitus tipo 2
Herrera, K. R. S., & Ayala, L. M. C. (2023) · ConcienciaDigital · doi:10.33262/concienciadigital.v6i4.2696
Shalhawi, B., & Joha, M. S. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00673
Kale, N., & Dighe, P. R. (2023) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v11i2.1214
“About 90% of all people are fat or overweight now at the time of T2D diagnosis, which leads several specialists to assume that the pathogenesis of the disease is induced by diets that involve excessive food consumption associated with decreased energy expenditure 6 .”
BackgroundSugiyanta, S., Rayyan, M. I. R., & Santosa, A. (2023) · Journal of Health Sciences · doi:10.33086/jhs.v16i03.4004 · Cited by 2
“It is characterized by persistent hyperglycemia caused by impaired insulin secretion, insulin action, or both (Reed et al., 2021).”
BackgroundNanoscience for Drug Delivery in Diabetes
Gupta, N. V., Koduru, T. S., Sharadha, M., Chakraborty, S., Kumar, H., Jain, V. K., & Dey, S. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010007
Shan, B. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v66i.11623
“T2D is the result of abnormal insulin levels caused by pancreatic β-cell dysfunction and the inability of insulin-sensitive organs (mostly in muscles, liver, and fat tissue) to respond correctly to insulin regulation [3].”
BackgroundSyndromes of severe insulin resistance: lessons from nature
Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00005-x
Diniz, H. J. C., da Silva, R. F., Camisasca, L. R., Silva, L. F., Alves, C. D. R., Rezende, L. F. D., de Magalhães, T. A., & Silva, C. S. D. O. E. (2024) · Revista Contemporânea · doi:10.56083/rcv4n2-007
Radiological Modalities and Diabetes: A Review
Kelis, K. M., Almutairi, A. D., Aldrewesh, T. A., Abubakar, D., & Almutairi, A. D. (2022) · Journal of Clinical Images & Reports · doi:10.47363/jcir/2022(1)123
Introduction to Lifestyle Diseases and Role of Herbal Medicines
Dhara, A. K., & Nayak, A. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-7703-1_1
Malek, A., Kanojia, D., Chauhan, H., Sathvara, N. A., Arumugam, P., & Mohan, D. B. (2024) · IEEE International Conference on Computing, Power and Communication Technologies (IC2PCT) · doi:10.1109/ic2pct60090.2024.10486331 · Cited by 1
“Insulin use altered physical function, mental health, pain, and quality of life [14].”
BackgroundTarget recognition of an RNA methyltransferase
Feußner, K. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10456
Variación de la presión arterial media en población peruana con y sin diabetes mellitus-2
Tirado, A. G. (2024) · REVISTA EUGENIO ESPEJO · doi:10.37135/ee.04.20.02
The Relationship Between Egg Consumption and Risk of Type 2 Diabetes in the Shahrekord Cohort Study
Ghafari, A., Arash, R., Jafari, T., Ahmadi, A., Tavassoli, E., & Shams-Abadi, A. D. (2024) · Epidemiology and Health System Journal · doi:10.34172/ehsj.26069
Nugroho, H., Mughni, A., Putranto, I. K. A., Prasetya, A. T., & Novitasari, V. (2024) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v16i3.3047 · Cited by 3
The Importance of Empowering Self-Management Skills in Diabetes Mellitus
Thapa, P. P., Oral, O., & Nomikos, G. N. (2024) · Advanced Medical Research · doi:10.62836/amr.v3i1.182
“…aspects of diabetes mellitus, as well as the rearrangement of medical treatment and individual management to preserve this metabolic balance [3]. https://ojs.sgsci.org/journals/amr In addition to medical treatment methods for the prevention and treatment of diabetes mellitus, another factor…”
BackgroundFarhan, A., Tariq, F., Aslam, M. M., Umair, M., Mirza, S., & Younis, B. B. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4893547
Exploring Multitargets Treatment for Diabetes
Akinsanola, B. A., Iyobhebhe, M. E., Maduakolam-Aniobi, T. C., Olaolu, T. D., Rotimi, D. E., & Ojo, O. A. (2024) · OBM Genetics · doi:10.21926/obm.genet.2403254
Exploring the Prevalence of Constipation in Diabetic Individuals in Qassim Region, Saudi Arabia 2024
Aloufi, M. A., Alqahtani, Q. Q., & Albedah, B. A. (2024) · Medical Science · doi:10.54905/disssi.v28i149.e86ms3396 · Cited by 2
Isolation and Identification of Enterococcus spp. Resistant to Macrolides Antibiotics
Molan, N. K., & Hussien, A. E. A. (2024) · Iraqi Journal of Science · doi:10.24996/ijs.2024.65.8.12 · Cited by 5
Athavale, V. S., & Athavale, P. V. (2024) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_917_23
Pointeau, O., Barbosa, R., Degrace, P., Vergès, B. L., & Jourdan, T. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.001
Current Treatment Options for Diabetes: A Review
Shrivastav, R., Koshti, S. V., Singh, A., & Tasgaonkar, R. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24oct1724
Hashim, R. D., Al-Sharifi, N. A. N., Nathir, I., & Aljubori, A. (2024) · Gaceta Médica Boliviana · doi:10.47993/gmb.v47i2.902
Amadi, C., Okafor, J. C., Otokunefor, O., & Agbo, E. O. (2024) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2024.6.6.2182
Identification of genetic loci enriched in obese or lean T2D cases in the Korean population
Lim, E. B., & Cho, Y. S. (2024) · Genes & Genomics · doi:10.1007/s13258-024-01602-x
Galib, R. K., Ahmad, A., Gundeti, M., Meena, R., Wilson, E., Itrat, M., Javed, G., Quamri, M. A., Singh, D., Yadav, P., et al. (2024) · doi:10.2196/preprints.70617
Tiwari, D. D., Thorat, V. M., & Pakale, P. V. (2025) · Cureus · doi:10.7759/cureus.78690
MUHAMMED, A. A., DAVID, J., Bello, Z., OGUNMEFUN, G. S., YUSUF, H. O., & Auta, R. (2024) · Journal of Biochemistry and molecular biology · doi:10.36108/jbmb/4202.20.0160
Madeswaran, A., & Mathivanan, V. (2025) · Biologica Nyssana · doi:10.46793/biolnyss.16.1.13m
Ideación suicida en adultos peruanos con riesgo de diabetes mellitus-2: un estudio analítico
Wiener, U. P. N., & Tirado, A. G. (2024) · Revista Facultad Nacional de Salud Pública · doi:10.17533/udea.rfnsp.e356362
A potential anti-amyloidogenic therapy for type 2 diabetes based on the QBP1 peptidePreprint
Tejero-Ojeda, M. M., Vives, A. B., Wojciechowski, M., Pham, D. Q. H., Chwastyk, M., Vallejo, M., Novials, A., & Carrión‐Vázquez, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.06.652241
“Among them, the aggregation-prone human islet amyloid polypeptide (hIAPP or amylin) is a major component of amyloid deposits in the pancreatic islets of patients with type 2 diabetes (T2D) (De Koning et al., 1994; Reed et al., 2021).”
Factors Affecting HbA1c According to Sleep Duration in Adults with Diabetes
Kwon, M., Kim, S., & Kim, J. (2025) · Diabetology · doi:10.3390/diabetology6060046 · Cited by 1
Beyond association: Examining overweight as a mediator in the link between depression and diabetes
Byeon, H. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.107071
Exploring marine metabolites for diabetes management: new horizons in diabetes treatment
Nelli, G., Salleh, N., Shah, H., & Das, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00017-6
Antidiabetic drugs and marketed formulations from natural products
Anywar, G., Adepoju, A. O., Kaggwa, B., & Mukungu, N. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00001-2
Psychometric Evaluation of the Beliefs About Stress Scale in the German General Population
Schmalbach, B., Schmalbach, I., Laferton, J. A. C., Strauss, B. M., Fegert, J. M., Brähler, E., & Petrowski, K. (2025) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.70026
Duojie, R., Chen, M., Li, C., Fu, W., Wang, X., Meng, X., Cairang, N., & Hou, Y. (2025) · Journal of Visualized Experiments · doi:10.3791/68319
Tirado, A. G. (2024) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v72n4.114974
Thanthrige, A. N. W., & Wickramasinghe, N. S. (2025) · doi:10.2196/preprints.80582
Chen, R., Zhao, H., Wu, S., Yang, N., Zhang, Z., Li, K., Chen, J., Wang, P., Liu, X., & Zhang, R. (2025) · Phycology · doi:10.3390/phycology5030036
Sardar, H., Noor, F., Shah, S. M., Khan, A. U., Al-Otaibi, J. S., Hadi, F., Daglia, M., & Khan, P. D. H. (2025) · Drug Target Insights · doi:10.33393/dti.2025.3495
“Many traditional treatments focus on only one element of the disease’s intricate pathophysiology, potentially resulting in less than ideal results and failing to stop the advancement of the disease (7).”
Alex, A. M., Vivek, S., & Edward, A. (2025) · Journal of Medico Informatics · doi:10.64659/jomi/209858 · Cited by 2
Rodrigues, L. C., Caldeira, T. C. M., Miranda, C., Veiga, I. P. A., de Sousa, T. M., & Claro, R. M. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251374739
“18 Evidence reinforces recommendations such as alcohol moderation, 24 physical activity for glycemic control, 24,25 and reduced ultra-processed food consumption.”
Emerging Insulin Analogues: A Glimpse into How Insulin Analogues May Look in the near Future
Sibiya, N. H., Dzimwasha, L., Zvandasara, S., Zuma, A., & Khathi, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101239 · Cited by 2
“The fear of hypoglycaemia is one of the reported reasons that leads to non-adherence to insulin therapy [103].”
Innovative nanotechnological approaches to diabetes treatment: the role of metal oxide nanoparticles
Shaban, E. E., & El-Aziz, M. E. A. (2025) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2566460 · Cited by 1
“It is distinct from pancreatic b -cell dysfunction, an increase in pancreatic a -cell function, and peripheral IR (Reed et al. 2021; Fitzpatrick et al. 2023).”
Pal, S., Si, S., Bindhani, B. K., Rao, G. N., & Pal, A. (2025) · DNA and cell biology reports. · doi:10.1177/29979811251362772
Scoping Review on 30-day Readmission Prediction in Diabetes Management Using Artificial Intelligence
Mishra, V., Tanniru, M. R., & Sreedharan, J. (2025) · Journal of Datta Meghe Institute of Medical Sciences University · doi:10.4103/jdmimsu.jdmimsu_597_24
Thanthrige, A. N. W., & Wickramasinghe, N. S. (2025) · doi:10.2196/preprints.86515
Hussein, H. Q., Haji, H., & MUSTAFA, M. D. M. Z. A. R. A. K. (2025) · Health Problems of Civilization · doi:10.5114/hpc.2025.155551
Pan, Z. Y., Cun, D., Wang, W., Zhao, J., Song, F., Qi, C., & Li, S. (2025) · Medicine · doi:10.1097/md.0000000000045288
“[8] Although genetic and environmental contributors have been identified, the causal links between diabetes and aging-related conditions (such as frailty) are not yet fully understood.”
Mosleth, E. F., Liland, K. H., Barajas-Olmos, F. M., Orozco, L., Lysenko, A., Ofstad, R., Mellgren, G., & Dankel, S. N. (2025) · Research Square · doi:10.21203/rs.3.rs-7053974/v1
Maiwé, D., Aboubakar, & Miaffo, D. (2025) · Food Chemistry Advances · doi:10.1016/j.focha.2025.101173
Diabetes Mellitus and the Increased Risk of Acute Kidney Injury Following Acute Coronary Syndrome
Shah, M. U., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Diabetology · doi:10.3390/diabetology6120148
“However, given that that approximately 90% of the population with diabetes comprises individuals with T2DM [27], the overall risk profile is likely to reflect type 2 as the predominant group.”
Risk of dementia in diabetes mellitus: a mechanistic endeavor
Samanta, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00029-3
Ghazala, S. J., El-Sawi, M. R., & El-Dein, M. A. (2025) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2025.610.631
Naima, J., Islam, M. R., Akter, B., Nahar, A., Jahan, N., Nisat, U. T., & Hossain, M. K. (2025) · Clinical Phytoscience · doi:10.1186/s40816-025-00397-y
“Recently, the exponential increase in diabetes has challenged the healthcare sector of the world which will affect 642 million people by 2040 [3].”
Mahdavi, A., Greffard, K., Trottier, J., Barbier, O., Bilodeau, J., Lebel, M., & Rudkowska, I. (2025) · Lifestyle Genomics · doi:10.1159/000550224
Селюкова, Н. Ю., Lurin, I. A., Tyzhnenko, T., & Misiura, K. V. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.8.2025.1661
Vitamin D deficiency and depression in diabetes mellitus: A systematic review and meta-analysis
Hernández-López, M., Grande‐Alonso, M., Aguado-Henche, S., Ramírez-Carracedo, R., Sebastián-Martín, A., & Moreno‐Gómez‐Toledano, R. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501743
Understanding the Connection Between Diabetes and Cancer
Sekar, P. K. C., & Veerabathiran, R. (2026) · Springer eBooks · doi:10.1007/978-981-95-5651-9_2
Guraka, A., Lush, M., Zouganelis, G., Waldron, J., Mekapothula, S., Masania, J., Cave, G. W. V., Conway, M. E., Tripathi, G., & Kermanizadeh, A. (2026) · Nutrients · doi:10.3390/nu18020279
Single nucleotide variant rs293795 OGG1 as a genetic risk factor for diabetic nephropathy
Семикина, Е. В., Эдуардовна, А. Ю., Panichev, S., Basareva, O., Джанчатова, Н. В., Алферова, Е. Ю., & Валерьевич, П. А. (2025) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2025.084
Son, J.-Y., Shin, S.-Y., Kim, J.-S., Kang, M., Lee, D.-H., Kim, J. H., Kim, C. W., Kang, B.-S., Han, G.-J., & Bang, M. (2025) · The Journal of Internal Korean Medicine · doi:10.22246/jikm.2025.46.6.1257 · Cited by 1
Ji, Y., Jiang, M., Wang, Z., Zhang, X., Cai, X., Guan, A., Zhao, J., He, Y., & Zeng, D. (2026) · Research Square · doi:10.21203/rs.3.rs-8594486/v1
Gul, S., Naseem, M., Sheikh, I. S., Ali, H. M., Rabbani, I., Jamil, T., Gul, S., Chachar, Z., Ullah, S., Asif, S., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1687575
Thanthrige, A. N. W., & Wickramasinghe, N. S. (2026) · JMIR Research Protocols · doi:10.2196/86515
“Young adults face rising chronic disease risks, particularly prediabetes, which affects approximately 374 million adults globally [9] and can be reversed through early lifestyle intervention [10].”
Ruknuddin, G., Ahmad, A., Gundeti, M., Meena, R., Wilson, E. G., Itrat, M., Javed, G., Quamri, M. A., Singh, D., Yadav, P., et al. (2026) · JMIR Research Protocols · doi:10.2196/70617
“Type 2 DM (T2DM) is the most prevalent form, accounting for over 90% of DM cases worldwide [2].”
Schäfer, L., Mályi, A., Seifert, G., Fink, M., Herrmann, S., Pohlen, U., Huegel, B., Bronsert, P., Fichtner-Feigl, S., Marjanovic, G., et al. (2026) · Frontiers in Surgery · doi:10.3389/fsurg.2026.1755398
“Its incidence has risen dramatically over the past decades (8–10).”
Panchani, D., Pawar, R., Kamdar, J. H., & Makasana, J. (2025) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428025601104
Single Nucleotide Variant rs3219484 MUTYH as a Genetic Predictor of Type 2 Diabetes Mellitus
Семикина, Е. В., Azarova, I. E., Алферова, Е. Ю., & Polonikov, A. (2026) · Russian Journal of Genetics · doi:10.1134/s1022795425701406
Kouam, A. F., Ngounou, E., Kongnyuy, K. J., Mokam, M. M., Tchamba, J. C. T., Menkem, E. Z., Fepa, A. G. K., Somene, F. S. D., Seukep, A. J., Njayou, F. N., et al. (2026) · South African Journal of Botany · doi:10.1016/j.sajb.2026.02.004
Srivastava, A., Jain, A., Patra, J., & Keshari, A. K. (2026) · Biointerface Research in Applied Chemistry · doi:10.33263/briac161.005
Vaithinathan, P., Dynika, T., Vaithiyanathan, S., Ganesan, C., & Mattyvanan, S. (2026) · Cureus · doi:10.7759/cureus.103942 · Cited by 1
Elhardalo, S. A. O. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20260655
Metadata
- Authors
- Reed, J., Bain, S., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Reed, Josh
- Bain, Stephen
- Kanamarlapudi, Venkateswarlu
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- Volume 14
- Pages
- 3567-3602
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8369920
- OpenAlex
- W3191601669
- Cited by
- 441
- References
- 326
- Citations by year
- 2026: 73 · 2025: 109 · 2024: 107 · 2023: 98 · 2022: 51 · 2021: 2
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Directorate for Biological Sciences
- Medical Research Council (G0401232)
- Biotechnology and Biological Sciences Research Council (BB/S019588/1, BB/F017596/1, BB/C515455/2, 1095087)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes epidemiology, diabetes aetiology, diabetes pathogenesis, impaired insulin secretion, glucagon-like peptide-1, incretins, GLP-1 receptor agonists, bariatric surgery alternatives, weight loss, diabetes complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.